Heather A. Wakelee
A5035640724- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Global Cancer Incidence and Screening
- Genetic factors in colorectal cancer
- Chronic Lymphocytic Leukemia Research
- Brain Metastases and Treatment
- Myasthenia Gravis and Thymoma
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Pancreatic and Hepatic Oncology Research
- PI3K/AKT/mTOR signaling in cancer
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
- Cancer Risks and Factors
Stanford University
2016-2025
Stanford Medicine
2015-2025
Cancer Prevention Institute of California
2015-2024
Stanford Cancer Institute
2015-2024
Cancer Institute (WIA)
2015-2024
Palo Alto University
2011-2024
Stratford University
2016-2024
Vanderbilt University Medical Center
2011-2023
Stanford Health Care
2015-2023
Brown University
2022
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization adjuvant therapies. Here, we apply personalized profiling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III 54 healthy adults. In 94% evaluable experiencing recurrence, ctDNA was detectable in the first posttreatment blood sample, indicating reliable...
Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by T790M most cases. Rociletinib (CO-1686) an inhibitor active preclinical models of EGFR-mutated NSCLC or without T790M.In this phase 1-2 study, we administered rociletinib patients who had disease progression during previous treatment existing inhibitor. In expansion (phase 2) part T790M-positive received...
Circulating tumour DNA (ctDNA) analysis facilitates studies of heterogeneity. Here we employ CAPP-Seq ctDNA to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib. We observe multiple 46% after treatment first-line inhibitors, indicating frequent intra-patient Rociletinib recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1. describe a novel EGFR L798I mutation...
Purpose Lung cancer is a leading cause of death worldwide. Although smoking remains the predominant lung cancer, in never smokers an increasingly prominent public health issue. However, data on this topic, particularly incidence rates smokers, are limited. Methods We reviewed existing literature and mortality among present new regarding from following large, prospective cohorts: Nurses’ Health Study; Professionals Follow-Up California Teachers Multiethnic Cohort Swedish Cancer Register...
Among patients with resectable early-stage non–small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either alone. Download PDF of the Research Summary. We conducted randomized, double-blind, phase 3 trial to evaluate pembrolizumab in NSCLC. Participants stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned 1:1 ratio receive (200 mg) placebo once every weeks, each which was given...
An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely direction to ASCO's membership following publication or presentation potentially practice-changing data from major studies. This PCO addresses the utility using epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer (NSCLC) predict benefit taking a first-line EGFR tyrosine kinase inhibitor (TKI).Patients EGFR-mutated NSCLC have significantly...
PURPOSE To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis. PATIENTS AND METHODS Adult patients with solid tumors were treated in four cohorts: part A, determine priming dose; B, weekly maintenance C, study loading dose week 2; tumor biopsy cohort. RESULTS Sixty-two treated: 11 14 22 15 Part A used doses ranged from 0.1 3 mg/kg. On basis tolerability receptor occupancy studies showed 100%...
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation drug resistance. We biopsied patients at rociletinib progression to explore resistance mechanisms. Among 12 T790M-positive initiation, six had T790-wild-type rociletinib-resistant biopsies. Two underwent small cell cancer transformation; three acquired amplification. documented and clones coexisting within single pre-rociletinib biopsy. The pretreatment...
Approximately 3% to 10% of EGFR (epidermal growth factor receptor) -mutant non-small cell lung cancers (NSCLCs) undergo transformation small-cell cancer (SCLC), but their clinical course is poorly characterized.We retrospectively identified patients with EGFR-mutant SCLC and other high-grade neuroendocrine carcinomas seen at our eight institutions. Demographics, disease features, outcomes were analyzed.We included 67 patients-38 women 29 men; mutations exon 19 deletion (69%), L858R (25%),...
Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non-small-cell lung cancer (NSCLC), regardless of brain metastases status and or without prior therapy an inhibitor the ALK protein. Data are presented from a phase II trial (ASCEND-2) which safety were evaluated who had NSCLC previously treated at least one platinum-based chemotherapy experienced progression during crizotinib treatment as their last therapy.Patients advanced NSCLC, including those asymptomatic...
Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response targeted therapies. Here, we present the results of an international registry patients with RET-rearranged NSCLCs, providing largest data set, our knowledge, outcomes RET-directed therapy thus far. Methods A global, multicenter network thoracic oncologists identified pathologically confirmed...
In approximately 60% of patients with NSCLC who are receiving EGFR tyrosine kinase inhibitors, resistance develops through the acquisition T790M mutation. We aimed to demonstrate that a highly sensitive and quantitative next-generation sequencing analysis mutations from urine plasma specimens is feasible.Short footprint mutation enrichment assays were used interrogate activating in or enrolled TIGER-X (NCT01526928), phase 1/2 clinical study rociletinib previously treated mutant-positive...
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple types, but whether further can improve outcomes patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 consolidation immune checkpoint inhibition (CICI). Patients undetectable after CRT had excellent or not they received CICI. Among such...